Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Published on by Cell Biologist

Dr. Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Dr. Sunila Pradeep | The Medical College of Wisconsin | United States

Dr. Sunila Pradeep, Ph.D., is an accomplished Associate Professor at the Medical College of Wisconsin, with over two decades of academic and research experience in immunology, oncology, and translational medicine. Originating from India, Dr. Pradeep began her journey in microbiology before delving deep into cancer research. Her multidisciplinary work bridges basic science with clinical relevance, particularly in ovarian and uterine cancers. Having trained in globally recognized institutions like the Weizmann Institute (Israel) and MD Anderson Cancer Center (USA), she has cultivated a robust research portfolio. Her impact in biomedical sciences is well-established. Dr. Pradeep’s ongoing work on extracellular vesicles, tumor microenvironment, and therapy resistance showcases her commitment to solving real-world clinical problems. A recipient of numerous national and international honors, she is a role model for aspiring women in science, blending scientific rigor with compassionate mentorship.

Publication Profile: 

Scopus

Education:

Dr. Sunila Pradeep’s academic path began in India, where she completed her B.Sc. and M.Sc. in Microbiology at Bharathiar University, Coimbatore, Tamil Nadu. Her passion for biomedical sciences led her to pursue a Ph.D. in Immunology at the University of Calicut, Kerala, under the mentorship of Dr. Girija Kuttan, where she began her exploration into natural compounds with anti-cancer properties. Her graduate studies laid a strong foundation in experimental biology and immunomodulation. Eager to expand her research horizons globally, she pursued postdoctoral training at the Weizmann Institute of Science in Israel, and later at the prestigious MD Anderson Cancer Center, Texas, USA, where she transitioned into translational cancer research. This diverse academic journey spanning three countries has given Dr. Pradeep a unique global perspective, rigorous research training, and an innovative approach to solving complex oncological challenges.

Professional Experience:

Dr. Sunila Pradeep has more than 18 years of research experience in oncology and immunology. Her professional career began with a Postdoctoral Fellowship at the Weizmann Institute, where she explored molecular signaling in cancer progression. She then advanced to a key fellowship role at the MD Anderson Cancer Center, focusing on therapeutic resistance in ovarian cancer. Since joining the Medical College of Wisconsin as an Associate Professor, she has established herself as a leading researcher in ovarian tumor microenvironments, metastasis mechanisms, and extracellular vesicle biology. Her role extends beyond research—she is also a dedicated mentor to graduate students and postdocs, and contributes to several multidisciplinary cancer initiatives. Dr. Pradeep’s scientific rigor, grant success, and translational insights have made her a sought-after collaborator. Her efforts to bridge laboratory research with clinical application reflect her commitment to improving outcomes for women suffering from gynecologic cancers.

Awards and Honors:

Dr. Pradeep’s distinguished career has been marked by several prestigious awards. She received the Fr. Gabriel Award from the Amala Institute of Medical Sciences, Kerala, recognizing her excellence in immunology research. During her tenure at MD Anderson Cancer Center, she was honored with the Trainee Excellence Award, reflecting her high-impact work in cancer biology. Her promising contributions to ovarian cancer research earned her the Scholar-in-Training Award from the Marsha Rivkin Center Foundation for Ovarian Cancer Research—a significant achievement for emerging leaders in gynecologic oncology. These accolades underscore her strong scientific foundation, innovation, and leadership in translational oncology. Beyond individual awards, her prolific publication record and active engagement in scientific communities amplify her impact. Dr. Pradeep’s recognition across three continents emphasizes her global footprint and her consistent commitment to advancing women’s health through science.

Research Focus:

Dr. Sunila Pradeep’s research revolves around understanding tumor biology, metastasis, angiogenesis, immunomodulation, and drug resistance in gynecologic cancers, particularly ovarian and uterine cancers. She investigates the role of extracellular vesicles, tumor-derived signals, and the tumor microenvironment in driving cancer progression and therapy evasion. Her lab explores novel biomarkers and targets for overcoming VEGF resistance, improving chemotherapy response, and modulating the immune system to suppress tumor growth. Her translational work includes identifying new combination therapies (e.g., selinexor with eribulin) and examining gut microbiota’s role in estrogen signaling—connecting metabolic and hormonal networks with cancer biology. She is also involved in cutting-edge research on RNA-binding proteins, such as FXR1, and their roles in mRNA translation in cancer. With cross-disciplinary collaborations and NIH-supported studies, her focus bridges fundamental discovery with real-world clinical applications. Her ultimate goal: to make therapies more precise, personalized, and effective for women with cancer.

Publications Top Notes: 

  1. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine

  2. Protective effect of Piper longum fruit ethanolic extract on radiation-induced damages in mice

  3. Expression of VEGF and VEGF receptors in tumor angiogenesis and malignancies

  4. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice

  5. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis

  6. Antimetastatic activity of Thuja occidentalis in a mouse model

  7. Inhibition of carcinogenesis by homeopathic drugs

  8. Effect of homeopathic medicines on transplanted tumors in mice

  9. Dynamized preparations in cell culture

  10. Phosphomimetic mutants of PEDF with enhanced antiangiogenic activity as anticancer agents

Conclusion:

Overall, Dr. Sunila Pradeep is highly qualified and a strong candidate for a Best Researcher Award in ovarian cancer research. Her prolific publication record, substantial citation impact, and focus on innovative cancer biology and treatment research provide a solid foundation for recognition. By highlighting her leadership contributions, translational impact, and broader scientific engagement, she can further strengthen her nomination. Her work clearly advances the field of ovarian cancer and serves as a model for impactful biomedical research, making her a deserving contender for such a prestigious award.

 

Ying Xu | Reproductive Pharmacology | Women Researcher Award

Published on by Cell Biologist

Prof. Ying Xu | Reproductive Pharmacology | Women Researcher Award

Prof. Ying Xu | China Academy of Chinese Medical Sciences | China

Dr. Ying Xu is a distinguished Professor and Doctoral Supervisor at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. With extensive expertise in reproductive pharmacology and Traditional Chinese Medicine (TCM), she has made significant contributions to understanding female reproductive health through innovative TCM-based research. Her prolific academic career spans over two decades, with a focus on pharmacology, germline stem cells, and metabolomics. She has authored over 30 peer-reviewed publications and received multiple national research awards. Dr. Xu is also a dedicated mentor, serving as a master’s and doctoral advisor in prestigious institutions such as the Shanghai University of Traditional Chinese Medicine. Her work bridges traditional knowledge and modern pharmacological techniques to explore therapeutic interventions for conditions like infertility, ovarian dysfunction, and hormonal imbalances. Through international collaboration and pioneering research, Dr. Xu has become a leading voice in integrating Eastern and Western medicinal paradigms.

Publication Profile: 

Scopus

Education:

Dr. Ying Xu received her Ph.D. in Pharmacology of Traditional Chinese Medicine in 2010 from the Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine. Her doctoral work laid the foundation for her research in reproductive pharmacology using traditional formulations. In 2009, she participated in academic visitor studies at London Metropolitan University, expanding her global research perspectives. She earned her M.S. in Traditional Chinese Medicine from Heilongjiang University of Traditional Chinese Medicine in 2006, and a B.S. in Biological Pharmacy from Jilin University in 2000. Dr. Xu’s academic journey reflects a strong grounding in biomedical sciences with a specialized focus on the integration of pharmacology and traditional practices. Her education path is a testament to a progressive, interdisciplinary approach, building the expertise required to explore TCM through modern scientific lenses, particularly in female reproductive and endocrine health.

Professional Experience:

Dr. Xu has served as Professor and Doctoral Supervisor at the Institute of Chinese Materia Medica since 2020, contributing to high-level academic leadership and guiding doctoral research. She has been a Master’s Supervisor at Shanghai University of Traditional Chinese Medicine since 2018, fostering the next generation of TCM researchers. Between 2014 and 2019, she held the position of Associate Professor at the same institute, where she led several important projects in reproductive pharmacology. Her role spans teaching, research, mentorship, and international collaboration. With nearly two decades of professional academic engagement, Dr. Xu’s experience is marked by consistent research productivity, leadership in laboratory-based studies, and significant contributions to national projects on women’s reproductive health. Her multidisciplinary approach combines classical TCM theories with modern biochemical and pharmacological techniques, leading to discoveries in ovarian reserve function, stem cell therapies, and hormonal disorders.

Awards and Honors:

Dr. Ying Xu has received several prestigious awards recognizing her innovative research in Traditional Chinese Medicine. Notably, she was the second recipient on three significant awards from the China Academy of Chinese Medical Sciences and the Chinese Association of Integrative Medicine:

  1. Science and Technology Progress Award (Second Prize, 2016) – for research on compatibility in TCM based on the Fanghai treatment.

  2. Science and Technology Progress Award (Second Prize, 2016) – for pharmacodynamic characterization in anti-compatibility TCM practices.

  3. Science and Technology Progress Award (Third Prize, 2013) – for her work on the effect of Coptis chinensis on hemolytic jaundice in neonates.

These awards validate her impactful contributions in merging traditional therapeutic insights with contemporary medical applications. Her work in women’s reproductive pharmacology using TCM formulations continues to attract national recognition and supports advancements in female health and fertility.

Research Focus:

Dr. Xu’s research focuses on the pharmacological mechanisms of Traditional Chinese Medicine, with a specialized interest in female reproductive health, ovarian reserve, hormonal regulation, and germline stem cell therapies. Using advanced techniques like metabolomics, UPLC/Q-TOF-MS, and Notch signaling pathway analysis, her studies investigate how TCM formulations like Cistanches Herba, Semen Cuscutae, and QingYan Formula impact fertility, menopause, and ovarian function. Her research spans both in vivo (animal models) and in vitro (cell-based) studies, aiming to decode the biochemical pathways behind TCM efficacy. Dr. Xu is especially interested in kidney-Yang deficiency models, ovarian germline stem cells, and endocrine system modulation. Her interdisciplinary work bridges classical TCM theory with modern pharmaceutical sciences, paving the way for evidence-based TCM applications in gynecology and reproductive endocrinology. This holistic yet data-driven approach positions her at the forefront of innovative, woman-centered integrative health research.

Publications Top Notes: 

  1. Cistanche total glycoside capsule promotes sperm maturation and fertility via the NELL2 Lumicrine pathway (J Ethnopharmacol, 2025)

  2. Cistanche deserticola improves ovariectomy-induced osteoporosis via lipid metabolism regulation (J Ethnopharmacol, 2024)

  3. QingYan Formula alleviates perimenopausal syndrome via UPLC-Triple-TOF-MS-based metabolomics (J Pharm Biomed Anal, 2024)

  4. Cistanches Herba and reproductive outcomes: A comprehensive review (Phytomedicine, 2024)

  5. Semen Cuscutae flavonoids protect ovarian germline stem cells via Notch signaling (Stem Cell Rev Rep, 2024)

  6. Triptolide’s reproductive toxicity in arthritic female rats (Zhongguo Zhong Yao Za Zhi, 2024)

  7. Isolation and culture of ovarian germline stem cells in mice (Genomics Appl Biol, 2023)

  8. Cuscutae Semen + Tripterygium tablets on ovarian germline stem cells (Chin J Exp Trad Med Formulae, 2023)

  9. Toxicity of Tripterygium glycosides on ovarian stem cells in vitro (Zhongguo Zhong Yao Za Zhi, 2024)

  10.  “Property-efficiency-pharmacology-disease” relationship in estrogen-like TCM (Chin Tradit Herbal Drugs, 2023)

Conclusion:

Dr. Ying Xu embodies the essence of a leading female scientist who blends tradition with innovation to advance women’s health research. Her deep expertise in reproductive pharmacology of Traditional Chinese Medicine, combined with a strong track record of mentorship, publication, and national recognition, makes her an ideal candidate for the Research for Women Researcher Award. Despite some opportunities for broader international visibility, her contributions to female reproductive science through stem cell research, hormonal regulation studies, and herbal pharmacology are profound and deeply influential. Her work not only advances academic understanding but also addresses real health challenges faced by women, particularly through culturally relevant medical approaches. Recognizing Dr. Xu with this award would not only honor her scientific achievements but also encourage the integration of diverse medicinal philosophies in global women’s health research.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.